ClinicalTrials.Veeva

Menu

Hybrid SA RGP Center/S-H Skirt Daily Wear 90 Day Multicenter Study

S

Synergeyes

Status

Completed

Conditions

Corneal Disease
Hypersensitivity

Treatments

Device: SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Contact Lens
Device: SynergEyes Hybrid (petrafocon A hem-larafilcon A) Hybrid Contact Lens

Study type

Interventional

Funder types

Industry

Identifiers

NCT00804505
SI-0804 V1.0

Details and patient eligibility

About

The purpose of the study is to demonstrate that the SynergEyes SA Hybrid Contact Lens clinical performance is substantially equivalent to that of the SynergEyes A Hybrid Lens when studied:

  • within the corresponding range of lens powers
  • in a population randomized within multiple investigational sites
  • with a study ration of 2/1 test vs control lenses
  • for a duration of 90 days.

Full description

The objective of the study is to compare the SynergEyes SA Hybrid Contact Lens (Test) to the SynergEyes A Hybrid Contact lens (Control) when used in a daily wear regimen on non-diseased eyes for the correction of myopia (-0.25 to -6.00Diopters) with up to -2.50 Diopters of astigmatism. The population will be randomized into a 2/1 ratio of the Test/Control for 90 days. The study objective is to complete at least 40 subjects in the Test material and 20 subjects in the Control material.

The purpose of the study is to demonstrate that the SynergEyes SA Hybrid Contact Lens clinical performance is substantially equivalent to that of the SynergEyes A Hybrid Lens when studied within the corresponding range of powers in a population randomized within investigational sites to produce a 2/1 ratio of Test vs. Control lenses.

Enrollment

98 patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Prior to being considered eligible to participate in this study, each subject MUST:

  1. Be at least 18 years of age as of the date of evaluation.

  2. Have

    1. read the Informed Consent,
    2. been given an explanation of the Informed Consent,
    3. indicated an understanding of the Informed Consent and
    4. signed the Informed Consent Form.
  3. Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments.

  4. Be a current contact lens wearer.

  5. Possess wearable and visually functional eyeglasses.

  6. Be in good general health, based on his/her knowledge.

  7. Require spectacle lens powers between plano and -6.00 diopters sphere with no more than -2.50 diopters of spectacle refractive astigmatism and be willing to wear lenses in both eyes.

  8. Have manifest refraction visual acuity equal to or better than 20/25 in each eye.

Exclusion criteria

  • Subjects may not be enrolled into the study if ANY of the following apply:

    1. Subject is wearing lenses in a monovision modality and is unwilling to be fit with distance lenses in both eyes. NOTE: Subjects may NOT wear monovision lenses at any time during the study as it will interfere with the distance visual acuity measurement.

    2. Subject exhibits poor personal hygiene.

    3. Subject is currently or within 30 days prior to this study has been an active participant in another clinical study.

    4. Subject is currently pregnant (to the best of the subject's knowledge), is planning a pregnancy within the next 3 months or is lactating.

    5. Subject is a member, relative or household member of the office staff, including the investigator(s).

    6. Subject has a known sensitivity to ingredients used in contact lens care products or over-the-counter lubricants and artificial tears.

    7. Subject has undergone refractive surgery or is currently receiving or has previously received orthokeratology treatment.

    8. Subject is aphakic or pseudophakic.

    9. Subject has ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome lupus erythematosus, scleroderma, keratoconus or type II diabetes.

    10. Use of ocular medications for any reason or systemic medications which might interfere with contact lens wear.

    11. A known history of corneal hypoesthesia (reduced corneal sensitivity).

    12. Slit lamp findings that would contraindicate contact lens wear, including but not limited to:

      • History of corneal ulcer, corneal infiltrates or fungal infections
      • Corneal scars within the visual axis
      • Pterygium
      • Dry eye symptoms with decrease tear levels and punctate staining ≥ Grade 2
      • Neovascularization or ghost vessels > 1.5 mm in from the limbus
      • Seborrhoeic eczema, seborrhoeic conjunctivitis
      • History of papillary conjunctivitis that has interfered with lens wear or a current condition of Grade 2 (Mild) or greater
    13. Clinically significant (Grade 3 or 4) anterior segment abnormalities or any infection of the eye, lids, or associated structures.

TO BE ELIGIBLE TO BE RANDOMIZED FOR STUDY PRODUCT TRIAL A SUBJECT MUST HAVE ALL OF THE INCLUSION CRITERIA AND NONE OF THE EXCLUSION CRITERIA PRESENT.

TO BE ELIGIBLE FOR LENS DISPENSING, THE SUBJECT'S STUDY DEVICE CONTACT LENS VISUAL ACUITY MUST BE EQUAL TO OR BETTER THAN 20/30 IN EACH EYE

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

98 participants in 2 patient groups

1
Experimental group
Description:
Test arm daily wear hybrid contact lens.
Treatment:
Device: SynergEyes Hybrid (petrafocon A hem-larafilcon A) Hybrid Contact Lens
2
Other group
Description:
Control: SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Hybrid Contact Lens
Treatment:
Device: SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Contact Lens

Trial contacts and locations

8

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems